Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Front Immunol ; 13: 754557, 2022.
Article in English | MEDLINE | ID: mdl-35663976

ABSTRACT

Delivery of plasmid DNA to transfect human primary macrophages is extremely difficult, especially for genetic engineering. Engineering macrophages is imperative for the treatment of many diseases including infectious diseases, cancer, neurological diseases, and aging. Unfortunately, plasmid does not cross the nuclear membranes of terminally differentiated macrophages to integrate the plasmid DNA (pDNA) into their genome. To address this issue, we have developed a core-shell nanoparticle (NP) using our newly created cationic lipid to deliver the anti-inflammatory cytokine IL-4 pDNA (IL-4pDNA-NPs). Human blood monocyte-derived macrophages (MDM) were effectively transfected with IL-4pDNA-NPs. IL-4pDNA-NPs were internalized in MDM within 30 minutes and delivered into the nucleus within 2 hours. Exogenous IL-4 expression was detected within 1 - 2 days and continued up to 30 days. Functional IL-4 expression led to M2 macrophage polarization in vitro and in an in vivo mouse model of inflammation. These data suggest that these NPs can protect pDNA from degradation by nucleases once inside the cell, and can transport pDNA into the nucleus to enhance gene delivery in macrophages in vitro and in vivo. In this research, we developed a new method to deliver plasmids into the nucleus of monocytes and macrophages for gene-editing. Introducing IL-4 pDNA into macrophages provides a new gene therapy solution for the treatment of various diseases.


Subject(s)
Gene Editing , Monocytes , Animals , DNA/metabolism , Humans , Interleukin-4/genetics , Interleukin-4/metabolism , Macrophages/metabolism , Mice , Monocytes/metabolism
2.
Sci Rep ; 11(1): 14898, 2021 07 21.
Article in English | MEDLINE | ID: mdl-34290273

ABSTRACT

Interleukin-27 (IL-27) is a cytokine that suppresses human immunodeficiency virus (HIV)-1 infection in macrophages and is considered as an immunotherapeutic reagent for infectious diseases. It is reported that IL-27 suppresses autophagy in Mycobacterium tuberculosis-infected macrophages; however, a role for IL-27 on autophagy induction has been less studied. In this study, we investigated the impact of IL-27 in both autophagy induction and HIV-1 infection in macrophages. Primary human monocytes were differentiated into macrophages using human AB serum (huAB) alone, macrophage-colony stimulating factor (M-CSF) alone, or a combination of IL-27 with huAB or M-CSF. Electron microscopy and immunofluorescence staining demonstrated that a 20-fold increase in autophagosome formation was only detected in IL-27 + huAB-induced macrophages. Western blot analysis indicated that the autophagosome induction was not linked to either dephosphorylation of the mammalian target of rapamycin (mTOR) or lipidation of microtubule-associated protein 1A/1B-light chain 3 (LC3), an autophagosomal marker, implying that IL-27 can induce autophagy through a novel non-canonical pathway. Here we show for the first time that IL-27 induces autophagy during monocyte-to-macrophage differentiation in a subtype-dependent manner.


Subject(s)
Autophagy/drug effects , Interleukins/pharmacology , Macrophages/drug effects , Macrophages/physiology , Microtubule-Associated Proteins , Signal Transduction/drug effects , TOR Serine-Threonine Kinases , Cell Differentiation , Cells, Cultured , Humans , Monocytes/physiology
3.
J Biomed Nanotechnol ; 14(10): 1785-1795, 2018 Oct 01.
Article in English | MEDLINE | ID: mdl-30041724

ABSTRACT

Convenient methods for the preparation of gene delivery platforms based on branched low molecular weight polyethylenimine (PEI) were described. Firstly, PEI lipids, with a low molecular weight PEI headgroup and hexadecyl chain tail group, were prepared through a highly efficient ring-opening reaction of glycidyl hexadecyl ether (EpoxyC16) by amine from PEI. Then, the PEI lipids were used as a component of cationic liposomes and as a surfactant for the preparation of poly(D,L-lactide-co-glycolide) (PLGA) nanoparticle (NP) via solvent extraction/evaporation method. As potential effective gene delivery platforms, their preparation, size, size distribution, toxicities, plasmid DNA loading, in vitro transfection and intracellular trafficking were studied. Both facile platforms showed less toxicity and higher transfection efficacy when compared to high molecular weight PEI in vitro, and may have further versatile applications in the gene delivery field.


Subject(s)
Polyethyleneimine/chemistry , Cell Survival , DNA , Drug Carriers , Molecular Weight , Particle Size , Plasmids , Transfection
4.
Oncotarget ; 8(4): 6564-6578, 2017 Jan 24.
Article in English | MEDLINE | ID: mdl-28036254

ABSTRACT

Nanoparticles containing mixed lipid monolayer shell, biodegradable polymer core and rabies virus glycoprotein (RVG) peptide as brain targeting ligand, were developed for brain targeted delivery of paclitaxel (PTX) to treat malignant glioma. RVG conjugated PTX loaded NPs (RVG-PTX-NPs) had the desirable size (~140 nm), narrow size distribution and spherical shape. RVG-PTX-NPs showed poor uptake by neurons and selective targeting to the brain tumor associated macrophages (TAMs) with controlled release and tumor specific toxicity. In vivo studies revealed that RVG-PTX-NPs were significant to cross the blood-brain barrier (BBB) and had specific targeting to the brain. Most importantly, RVG-PTX-NPs showed effectiveness for anti-glioma therapy on human glioma of mice model. We concluded that RVG-PTX-NPs provided an effective approach for brain-TAMs targeted delivery for the treatment of glioma.


Subject(s)
Antineoplastic Agents/administration & dosage , Brain Neoplasms/drug therapy , Drug Carriers , Glioma/drug therapy , Macrophages/drug effects , Nanoparticles , Paclitaxel/administration & dosage , Animals , Antineoplastic Agents/chemistry , Antineoplastic Agents/metabolism , Antineoplastic Agents/toxicity , Blood-Brain Barrier/metabolism , Brain Neoplasms/metabolism , Brain Neoplasms/pathology , Capillary Permeability , Cell Line, Tumor , Coculture Techniques , Delayed-Action Preparations , Dose-Response Relationship, Drug , Drug Compounding , Drug Design , Glioma/metabolism , Glioma/pathology , Glycoproteins/metabolism , Humans , Lactic Acid/chemistry , Ligands , Lipids/chemistry , Macrophages/metabolism , Macrophages/pathology , Male , Mice, Inbred BALB C , Mice, SCID , Neurons/metabolism , Paclitaxel/chemistry , Paclitaxel/metabolism , Paclitaxel/toxicity , Peptide Fragments/metabolism , Polyglycolic Acid/chemistry , Polylactic Acid-Polyglycolic Acid Copolymer , Time Factors , Tissue Distribution , Viral Proteins/metabolism , Xenograft Model Antitumor Assays
5.
Tuberculosis (Edinb) ; 101S: S18-S27, 2016 12.
Article in English | MEDLINE | ID: mdl-27727129

ABSTRACT

Tuberculosis continues to be a great cause of morbidity and mortality in different parts of the world. Unfortunately, the current BCG vaccine being administered is not fully protective against tuberculosis; therefore, there is a great need for alternate vaccines. With an aim to develop such vaccines, we have analyzed the utility of Bacillus subtilis spores for the expression of two major immunodominant antigens of Mycobacterium tuberculosis, Ag85B and CFP10. We created three recombinant B. subtilis strains to express a truncated fusion of Ag85B191-325 and CFP101-70 antigens (T85BCFP), either on the spore coat (MTAG1 strain) or in the cytosol of B. subtilis (MTAG 2 and MTAG 3 strains). Examination of spores isolated from these strains revealed successful expression of T85BCFP antigens on the spore coat of MTAG1 as well as in the cytosol of vegetatively grown cells of MTAG2 and MTAG3, indicating that spores can indeed express M. tuberculosis antigens. In vitro antigen presentation assays with spore-infected mouse bone marrow derived macrophages (BMDM) showed that all three recombinant spores could deliver these antigens to antigen presenting cells (APCs). Mice immunized with recombinant spores displayed significantly higher levels of Ag85B specific IFN-γ producing cells in the spleen than in mice immunized with wild-type (non-recombinant) spores. In addition, these mice showed relatively higher levels of Ag85B specific IgG antibodies in the serum in comparison to mice immunized with non-recombinant spores, thus providing additional evidence that recombinant spores can deliver these antigens in vivo. These results suggest that B. subtilis spores are ideal vehicles for antigen delivery and have great potential in the development of primary and booster vaccines against tuberculosis.


Subject(s)
Acyltransferases/administration & dosage , Antigens, Bacterial/administration & dosage , Bacillus subtilis/metabolism , Bacterial Proteins/administration & dosage , Genetic Vectors , Spores, Bacterial , Tuberculosis Vaccines/administration & dosage , Acyltransferases/biosynthesis , Acyltransferases/genetics , Acyltransferases/immunology , Administration, Intranasal , Animals , Antibodies, Bacterial/blood , Antigens, Bacterial/biosynthesis , Antigens, Bacterial/genetics , Antigens, Bacterial/immunology , Bacillus subtilis/genetics , Bacillus subtilis/immunology , Bacterial Proteins/biosynthesis , Bacterial Proteins/genetics , Bacterial Proteins/immunology , Cells, Cultured , Female , Immunity, Cellular , Immunity, Humoral , Immunization , Immunoglobulin G/blood , Interferon-gamma/immunology , Interferon-gamma/metabolism , Macrophages/immunology , Macrophages/metabolism , Mice, Inbred C57BL , Recombinant Fusion Proteins/administration & dosage , Recombinant Fusion Proteins/biosynthesis , Recombinant Fusion Proteins/immunology , Spleen/immunology , Spleen/metabolism , Tuberculosis Vaccines/biosynthesis , Tuberculosis Vaccines/genetics , Tuberculosis Vaccines/immunology , Vaccines, Synthetic/administration & dosage , Vaccines, Synthetic/biosynthesis , Vaccines, Synthetic/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...